SAN DIEGO, Aug. 13, 2019 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that it has been awarded three distinct
patents in the U.S., Canada, and
Europe: U.S. Patent No. 10,369,568
entitled CELL SEPARATION USING MICROCHANNEL HAVING PATTERNED POSTS;
Canadian Patent No. 2,756,493 entitled DEVICES AND METHODS OF CELL
CAPTURE AND ANALYSIS; and European Patent No. 2,619,588 entitled
METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION.
The U.S. issued patent broadly covers methods and apparatus used
for the capture of target biomolecules, including cells of
interest, using microchannels that disrupt flow to aid capture. The
Canadian patent covers the capture of target cells, including CTCs,
using a combination of binding partners and methods for capture on
any surface. The European patent encompasses methods for enhancing
the detection of cells using fluorescent complexes. The combination
of these patents significantly expands the breadth of intellectual
property protection for Biocept's technologies in terms of their
applications and global reach. These three new patents expand
Biocept's intellectual property estate to 36 issued patents
globally.
"Collectively, the granting of these additional patents further
broadens Biocept's U.S. and international footprint for capturing
and analyzing any biological target of interest," said Lyle Arnold, Ph.D., Chief Scientific Officer at
Biocept. "For Biocept's core business, this includes CTCs from
any sample type, however these patents also expand the use of
Biocept's technologies well beyond its current core business and
may provide opportunities to out-license our technologies for a
variety of uses."
"Increasing shareholder value by broadening U.S. and
international patent protection used in our Target Selector™ liquid
biopsy platform is a key strategic initiative, as we seek to
develop our business globally, with the potential to license our
technologies for uses outside the scope of our core business," said
Michael Nall, Biocept President and
CEO. "We now have been granted 36 issued patents covering our
tests and technologies, and plan to continue to strengthen our
intellectual property position with additional patent issuances to
come."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with information for
treating and monitoring patients diagnosed with cancer. The
Company's patented Target Selector™ liquid biopsy technology
platform captures and analyzes tumor-associated molecular markers
in both circulating tumor cells (CTCs) and in plasma (ctDNA). With
thousands of tests performed, the platform has demonstrated the
ability to identify cancer mutations and alterations to inform
physicians about a patient's disease and therapeutic options. For
additional information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including,
without limitation, statements as to our ability to improve the
management, diagnosis and treatment of cancer, the ability of our
tests to provide clinically actionable information to oncologist
and their patients, our ability to expand our business globally and
expand the adoption of our tests, and opportunities to license our
technologies for a variety of uses, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-receives-three-additional-patents-covering-its-antibody-and-microchannel-technology-and-enhanced-detection-of-cancer-cells-300900469.html
SOURCE Biocept, Inc.